Evaluating nivolumab plus gemcitabine–cisplatin’s cost-effectiveness for aUC in China
Authors
- Mei-Yu Wu (ORCID: https://orcid.org/0009-0005-4991-4422)
- Ouyang Xie
- Heng Xiang
- Chongqing Tan (ORCID: https://orcid.org/0000-0002-6007-4170)
- Andong Li (ORCID: https://orcid.org/0000-0001-5291-2720)
- Kehui Meng
- Xiaomin Wan
Institutions
- Central South University (CN)
- Second Xiangya Hospital of Central South University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-11-05
- DOI
- https://doi.org/10.3389/fphar.2024.1382342
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- National Natural Science Foundation of China